| Schedule of segment net loss, including significant segment expenses |
The table below is a summary of the segment net loss, including significant segment expenses (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | THREE MONTHS ENDED | | SIX MONTHS ENDED | | JUNE 30, | | JUNE 30, | | 2026 | | 2025 | | 2026 | | 2025 | Operating expenses: | | | | | | | | | | | | Discovery research and development | $ | 23,079 | | $ | 26,244 | | $ | 41,596 | | $ | 48,031 | Manufacturing | | 15,278 | | | 133 | | | 19,548 | | | 133 | Clinical research and development | | 49,859 | | | 23,016 | | | 85,055 | | | 40,173 | Other research and development expenses | | 11,841 | | | 5,317 | | | 20,365 | | | 9,240 | General and administrative | | 18,573 | | | 15,741 | | | 41,445 | | | 29,185 | Total operating expenses | | 118,630 | | | 70,451 | | | 208,009 | | | 126,762 | Loss from operations | | (118,630) | | | (70,451) | | | (208,009) | | | (126,762) | Interest and other income, net | | 12,705 | | | 8,929 | | | 26,306 | | | 18,505 | Loss before provision for income taxes | | (105,925) | | | (61,522) | | | (181,703) | | | (108,257) | Provision for income taxes | | 234 | | | 139 | | | 424 | | | 237 | Segment net loss and net loss attributable to ordinary shareholders | $ | (106,159) | | $ | (61,661) | | $ | (182,127) | | $ | (108,494) | | | | | | | | | | | | |
|